Landmark Bio is an advanced cell and gene therapy manufacturing company — strategically located in the heart of the Boston life sciences ecosystem — focused on the development of innovative technologies, products, and services with the explicit mission to translate groundbreaking research into life-changing therapies. Formed by a unique consortium of Boston's universities, hospitals, and bioscience companies, Landmark Bio partners with a wide range of clients: academic researchers vetting therapeutic targets, physician scientists preparing IND filings, biopharmas advancing pipeline product to the clinic. The company's 44,000-sq.-ft. facility in Watertown, Massachusetts, offers broad development and manufacturing capabilities. Subsequently acquired by Artis BioSolutions in 2025, the company remains an independent entity.